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ABSTRACT 
Cyclooxygenase-2 (COX-2), a rate limiting step in arachidonic acid cascade, plays a key role 
in the biosynthesis of prostaglandin E2 (PGE2) upon inflammatory stimuli, growth factors, 
hormones and other cellular stresses. Overproduction of PGE2 stimulates proliferation of 
various cancer cells, confers resistance to apoptosis and favors metastasis and angiogenesis. 
The steady-state level of PGE2 is maintained by interplay between the biosynthetic pathway 
including COX and PGE2 synthases and the catabolic pathways involving nicotinamide 
adenine dinucleotide (NAD
+
)-dependent 15-hydroxyprostaglandin dehydrogenase (15-
PGDH). 15-PGDH is a crucial enzyme responsible for the biological inactivation of PGE2. 
Adult hepatocytes fail to induce COX-2 expression regardless of the pro-inflammatory factors 
used. COX-2 is induced in hepatocytes after partial hepatectomy (PH), in animal models of 
cirrhosis, in human hepatoma cell lines, in human HCC and after HBV and HCV infection. 
However, no data are available regarding 15-PGDH expression in HCC. Our results show that 
15-PGDH is downregulated in human hepatoma cells with a high COX-2 expression, in 
chemical and genetic murine models of HCC and in human HCC biopsies. Moreover, 15-
PGDH expression is suppressed by EGF (epidermal growth factor) and HGF (hepatocyte 
growth factor) mainly involving PI3K (phosphatidylinositol-3-kinase), ERK (extracellular 
signal-regulated kinase) and p38MAPK (mitogen-activated protein kinase) activation. 
Conversely, ectopic expression of 15-PGDH induces apoptosis in hepatoma cells and 
decreases the growth of hepatoma cells in nude mice whereas the silencing of 15-PGDH 
increases the tumor formation. These data suggest a potential therapeutic application of 15-
PGDH in HCC. 
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1. INTRODUCTION 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and has an 
increasing incidence in western countries (Llovet and Bruix, 2008). Although the risk factors 
for HCC are well characterized, the molecular pathogenesis of this tumor type is not well 
understood, and thus the identification of new possible targets for the development of non-
conventional treatments is urgent and must be improved (Hoshida et al. , 2009, Lee et al. , 
2004). 
Cyclooxygenase-1 (COX-1) and -2 catalyze the first step in prostanoid biosynthesis. COX-1 
is constitutively expressed in many tissues, whereas COX-2 is induced by a variety of stimuli 
such as growth factors, pro-inflammatory stimuli, hormones and other cellular stresses 
(Simmons et al. , 2004). Adult hepatocytes fail to induce COX-2 expression regardless of the 
pro-inflammatory factors used (Martin-Sanz et al. , 1998). However, our group and others 
demonstrated that partial hepatectomy (PH) induced COX-2 in hepatocytes and contributed to 
the progression of cell cycle after PH (Casado et al. , 2001, Rudnick et al. , 2001). In addition 
to liver regeneration after PH, expression of COX-2 has been observed in animal models of 
cirrhosis (Yamamoto et al. , 2003), in human hepatoma cell lines (Kern et al. , 2006, Mayoral 
et al. , 2005), in human HCC (Cusimano et al. , 2009) and after HBV and HCV infection 
(Cheng et al. , 2008, Nunez et al. , 2004). The second key enzyme that couples with COX-2 
for the synthesis of PGE2 is PGE2 synthase (PGES). Three types of PGES participating in the 
synthesis of PGE2 have been described: one cytosolic (cPGES) and two membrane-associated 
PGES (mPGES-1 and -2). Coupling with COXs, these two types of PGES display different 
functions. cPGES is a cytosolic protein identical to the Hsp90-associated protein 23, which is 
a cofactor for the molecular chaperone function of Hsp90. It is constitutively expressed in 
many cell types and is predominantly coupled with COX-1. mPGES-1 is an inducible enzyme 
which belongs to the membrane-associated proteins involved in eicosanoid and glutathione 
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metabolism (MAPEG) superfamily, catalyzes the synthesis of PGE2 commonly found in 
epithelial cells and is upregulated during inflammatory conditions (Diaz-Munoz et al. , 2012, 
Subbaramaiah et al. , 2004). Recently, more evidence has suggested that mPGES-1 
participates in various pathophysiological states in which COX-2 is involved. Consistent with 
the role of mPGES-1 for PGE2 synthesis, mPGES-1 knockdown has been shown to inhibit 
PGE2 production and reduce tumor proliferation and/or invasiveness of several tumor cell 
types including Lewis lung carcinoma cells, human prostate cancer cell lines and colorectal 
cancer cells, through a novel EGR1/β-catenin signaling axis (Sasaki et al. , 2011). 
In tumors the steady-state level of PGE2 is maintained by the biosynthetic pathway including 
both types of PGES, mPGES and cPGES and the catabolic pathways involving 15-PGDH. 15-
PGDH is a crucial enzyme responsible for the biological inactivation of PGE2 which induces 
cell proliferation, migration, angiogenesis and tumor metastasis (Na et al. , 2011). 15-PGDH 
metabolizes PGE2 by oxidizing the 15(S)-hydroxyl group into a keto group producing 15-keto 
PGE2 (Tai et al. , 2006). Genetic deletion of 15-PGDH leads to increased tissue levels of 
PGE2. Although previous studies on the distribution and activity of 15-PGDH have focused 
primarily in parturition and uterine biology, recent data suggest that 15-PGDH plays an 
important role in carcinogenesis. 15-PGDH is a tumor suppressor in gastrointestinal, 
colorectal, breast and lung cancers (Ding et al. , 2005, Wolf et al. , 2006, Yan et al. , 2004). 
However, a high expression of 15-PGDH as well as COX-2 was observed in a malignant 
ovarian tissue and the expression of 15-PGDH was induced by some cytokines, by the tumor 
promoter phorbol 12-myristate 13 acetate (PMA) and by sex hormone, suggesting a possible 
involvement of this enzyme in the carcinogenic process as well (Tong and Tai, 2004). 
Keeping in mind these data we evaluated the potential role of 15-PGDH in hepatoma cells. 
Our results show that 15-PGDH is downregulated in those human hepatoma cells with a high 
COX-2 expression, in chemical and genetic murine models of HCC and in human liver HCC 
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biopsies. Moreover, 15-PGDH expression is regulated by EGF and HGF mainly through 
PI3K, ERK and p38 MAPK and over expression of 15-PGDH induces apoptosis in hepatoma 
cells.   
2. MATERIALS AND METHODS 
2.1. Patients: Eighteen individual tumoral and paired non-tumoral frozen HCC tumors were 
obtained from de Spanish Tumor Bank Network of the Centro Nacional de Investigaciones 
Oncológicas (CNIO). Institutional review board approval (Nº PI. CEI PI 20_2011) was 
obtained for these studies and all participants provided written informed consent. All tissues 
were evaluated by pathologists by means of hematoxylin/eosin staining. Tissues were snap-
frozen in liquid nitrogen and total RNA was isolated as described in supplementary. 
2.1.1. Immunohistochemical staining: 2-4 µm thick paraffin-embedded tissue microarrays 
(TMAs) and complete sections were cut onto Dako slices (DAKO, Glostrup, Denmark) by 
Immunohistochemistry Unit of CNIO, and subsequently dewaxed, rehydrated and subjected 
to antigen retrieval by heating in PTLink with 50 mM Tris/EDTA, pH 9.0. The slides were 
cooled and treated with peroxidase-blocking solution (DAKO) for 5 min. Sections were 
immunostained with a 15-PGDH antibody (NeoMarkers, Suffolk, UK), in a Autostainer Plus 
(DAKO). In parallel, each tissue section was also incubated with a goat anti-rabbit antiserum 
(negative control). Microphotographs were taken with an EnVision FLEX system. The 
images were processed with Image J software. Integrated density was calculated for each 
image after background subtraction. The background corresponds to the immunoreactivity in 
the positive control tissue (normal liver).  
2.1.2. Animal models: Mice (25-30g body weight) on a C57BL6JxDBA background were 
used in this study. The animals were housed on a 12 h light/12 h dark cycle in an air 
conditioned room at 25ºC with food and water available ad libitum. To induce HCC, 
diethylnitrosamine (DEN) (25 mg/Kg body weight, Sigma) was injected intraperitoneally 
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(i.p.) into 14 day old mice. Mice were sacrificed at 10 and 40 wk after DEN treatment, their 
body and liver weights were recorded and their livers removed and separated into individual 
lobes. Mice were characterized as described by Llorente Izquierdo et al. (Llorente Izquierdo et 
al. , 2011).  Liver tissues were snap frozen in liquid nitrogen and stored at -80ºC. Moreover, a 
genetic model of HCC was used. Alb-c-myc (c-myc) and MT-TGF-α (TGF-α) single-
transgenic mice were kindly obtained from Dr. S.S. Thorgeirsson (National Cancer Institute, 
Bethesda, Maryland). Generation of c-myc/TGF-α double transgenic mice was achieved by 
crossing homozygous B6CBA c-myc and CD-1 TGF-α mouse as described previously 
(Santoni-Rugiu et al. , 1998). Expression of TGF-α driven by metallothionein I promoter was 
maintained by giving mice 50 mM ZnCl2 in drinking water starting at weaning. All the 
experiments were performed in accordance with the animal care guidelines of the European 
Union (2010/63/EU), and approved by the Bioethical Committee from Consejo Superior de 
Investigaciones Científicas (reference project SAF2010/16037). Male were sacrificed after 5 
and 9 months of age and their body and liver weights were recorded before the liver tissues 
were used for analysis. Wt mice were sacrificed at 9 months-old. Externally visible tumors (> 
0.5mm) were analyzed using the Metamorph software (Universal Imaging Corp, West 
Chester, PA, USA). Liver tissues were snap frozen in liquid nitrogen and stored at -80ºC or 
fixed in 10% buffered formalin. Plasma was obtained from cardiac puncture or from the aorta.  
2.1.3. Cell culture: The human liver cell lines WRL68, Chang liver (CHL) and the 
hepatoma cell lines HepG2 and Hep3B were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). HuH-6 and HuH-7 cell lines were kindly provided 
by Dr. Perret (Institut Cochin, CNRS UMR8104, University Paris-Descartes, Paris, France) 
(de La Coste et al. , 1998) and Dr. Kern (Department of General Pathology, University 
Hospital Heidelberg, Heidelberg, Germany) (Kern et al. , 2002), respectively. Human cell 
lines authentication and intra-species cell line cross-contamination were analyzed using 
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Promega’s StemElite™ ID System for the following STRs (short tandem repeats): D21S11, 
TH01, TPOX, vWA, CSF1PO, D16S539, D7S820, D13S317 and D5S818; Amelogenin was 
also analyzed for gender identification together with an specific marker for mouse DNA. 
STRs were analyzed with the Applied Biosystems® 3130xl Genetic Analyzer in the 
Genomics Core Facility of the Instituto de Investigaciones Biomédicas Alberto Sols CSIC-
UAM.  Cells were expanded twice, and stored in liquid N2. Expansions from these clones 
were used up to 6 months in culture. Cells were grown on DMEM supplemented with 10% 
FBS and antibiotics (50 g each of penicillin, streptomycin and gentamicin per ml). The cells 
were treated with EGF, HFG, 5 µM PGE2 and the following pharmacological inhibitors: 1 
µM Erlotinib (epidermal growth receptor), 20 µM LY29402 (phosphatidylinositol-3-kinase), 
10 µM PD98059 (MEK/ERK), 20 µM SB202190 (p38 MAPK), 1 µM Gö6983 (protein 
kinase C) and 5 µM DFU (5,5-dimethyl-3(3-fluorophenyl)-4-(4-methylsulfonyl) phenyl-
2(5H)-furanone) (COX-2) (MSD; Rhaway, NJ, USA). Timing and concentration curves were 
performed previously to determine the optimal concentrations of EGF. 
2.1.4. Analysis of tumorigenicity in nude mice: Female athymic nu/nu mice (6 weeks old) 
were obtained from Charles River Laboratories (Wilmington, MA). The animals were kept 
under pathogen-free conditions and were given an autoclaved standard diet and water ad 
libitum. HepG2 cells were transfected with pcDNA3/15-PGDH (3 µg) or control vector (3 µg) 
and with 30 nM siPGDH or 30nM scRNA using lipofectamine 2000 (Invitrogen, USA) 
according to the manufacturer´s instructions. At 48 h after transfection, 10x10
6 
viable cells 
suspended in PBS were injected subcutaneously into both flanks of the nu/nu mice (8 mice 
per group). Tumor growth was measured every 2 or 3 days. At 21 days after injection, mice 
were killed and tumors were weighed after necropsy. Tumor volume (V) was monitored by 
measuring the length (L) and width (W) with calipers and calculated with the formula (L x 
W
2
) x 0.5. 
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2.1.5. Data analysis: Data are expressed as mean ± S.D. (n ranged from three to five 
independent experiments or 8-12 mice per group). Statistical significance was estimated by 
one way analysis of variance (ANOVA) coupled Dunnett's Multiple Comparison Test for 
unpaired observations. Spearman r test for nonparametric correlations and Mann-Whitney U 
test was used for ordinal variables using the statistical software GraphPad Prism 5. A P value 
<0.05 was considered significant. 
3. RESULTS 
3.1. 15-PGDH and COX-2 expression correlate inversely in hepatoma cell lines. COX-2, 
mPGES-1 and 15-PGDH protein and mRNA levels were analyzed in four hepatoma (HCC) 
cell lines (HepG2, Hep3B, HuH-7, HuH-6), in a cell line derived from human liver embryo 
(WRL68) and in a cell line derived from normal liver (CHL), using human hepatocytes (HH) 
as control (Fig. 1A-D). Each cell line expresses different levels of COX-2, mPGES-1 and 15-
PGDH mRNA and protein. WRL68 exhibited the highest COX-2 and mPGES-1 expression 
levels followed for Hep3B and HuH-7 liver carcinomas, whereas CHL, HepG2 and HuH-6 
showed low levels of COX-2 and mPGES-1 (Fig. 1A-B-C). Interestingly, the COX-2 
positive-expression cell lines WRL68, Hep3B and HuH-7 displayed the lowest 15-PGDH 
mRNA and protein levels (Fig. 1A-D). PGE2 levels correlate with those of the COX-2 and 
mPGES-1 expression, as well as the decrease of 15-PGDH levels (Fig. 1E). To determine 
whether exits a relationship between COX-2 and 15-PGDH expression in the HCC cell lines, 
the COX-2 protein/15-PGDH protein ratio was calculated showing an inverse linear 
correlation (R
2
=0.8524, P=0.0238) (Fig. 1F).  
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3.1.1. 15-PGDH is downregulated by EGF in hepatic human cell line. 
Previous reports indicated that EGF and HGF challenges upregulate COX-2 and 
downregulate 15-PGDH expression in several carcinomas (Donnini et al. , 2011, Moore et al. 
, 2009, Tai et al. , 2011). Our results demonstrate that EGF increased COX-2 and mPGES-1 
levels in CHL cells (Fig. 2A). In addition to this, EGF decreased 15-PGDH protein levels in a 
concentration-dependent manner (Fig. 2A). Moreover, treatment of CHL cells with 50 ng/ml 
of EGF induced a marked increase of COX-2 and mPGES-1 protein and mRNA levels that 
reached a maximum at 48h and 6h, respectively (Fig. 2B-C). Furthermore, 50 ng/ml of EGF 
downregulated 15-PGDH protein and mRNA levels (Fig. 2B). Next, we decided to investigate 
the participation of HGF in the regulation of 15-PGDH expression. HGF induced COX-2 and 
mPGES-1 and reduced the 15-PGDH protein levels in CHL cells in a concentration-
dependent manner (Fig. 2D). To substantiate further our results, we examined whether EGF 
participates in the regulation of 15-PGDH expression in the hepatoma cell lines HepG2 and 
HuH-6. EGF induced mPGES-1 and COX-2 expression in HepG2 and HuH-6 cells 
(Supplementary Fig. S1A-B). Additionally, EGF decreased 15-PGDH expression in a 
concentration-dependent manner in HepG2 and HuH-6 cell lines (Supplementary Fig. S1A-
B).  
3.1.2. 15-PGDH decrease induced by EGF involves EGFR, PI3K, MEK /ERK-MAPK and 
p38-MAPK signaling pathways in CHL cells. 
CHL cells were incubated with different pharmacological inhibitors of key regulatory 
pathways and then challenged with EGF. Fig. 3A shows that COX-2 expression was 
downregulated by LY29402 and Erlotinib, suggesting that EGF-induced COX-2 expression 
was EGFR-dependent and involved PI3K signaling. Furthermore, 15-PGDH protein levels 
were upregulated by LY29402, SB202190, PD98059 and Erlotinib (Fig. 3A) suggesting that 
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15-PGDH expression decreased by EGF was EGFR-dependent and involved PI3K, p38 
MAPK and MEK/ERK MAPK signaling. Next, we investigate whether exogenous PGE2 
participates in the 15-PGDH downregulation induced by EGF in CHL cells. As Fig. 3B 
shows, COX-2 protein levels were not modified by treatment with DFU and PGE2. In parallel 
15-PGDH protein levels were not altered after COX-2 inhibition with DFU; however, PGE2 
treatment increased 15-PGDH protein levels, suggesting a positive feed-back mechanism, 
which is interrupted by EGF (Fig. 3B). To substantiate further our results, HepG2 and CHL 
cells were silenced for 15-PGDH using specific siRNAs. COX-2 expression increased and the 
opposite was found when the cells were transfected with an expression vector for 15-PGDH. 
Moreover, when WRL68 cells were silenced for COX-2 using specific siRNAs, 15-PGDH 
expression increased. These results suggest a complex interplay between COX-2 and 15-
PGDH in some hepatoma cells (Supplementary Fig. S2A-C). 
3.1.3. 15-PGDH expression decreases HCC cell viability and induces apoptosis.  
To further evaluate the effect of 15-PGDH in HCC cells outcome, we tested whether 15-
PGDH targeting, modulates cell viability or cell cycle in HCC cells. Overexpression of 15-
PGDH significantly decreased cell viability and promoted apoptosis in HepG2 and CHL cells 
(Fig. 4B, D-E and Supplementary Fig. S3B, D-F) whereas silencing of 15-PGDH with a 
siPGDH promoted an increase in cell viability and in a subset of cells growing in S-phase 
(Fig. 4B-C and Fig. S3B-C-E). Furthermore, 15-PGDH overexpression induced a decrease in 
G0/G1 and G2 phase cells (Fig. 4D and S3D-F) and an increase (219%) in apoptosis (Fig. 4E). 
Apoptosis was confirmed by measurement of caspase-3 activity and the expression of some 
pro- and anti-apoptotic proteins. 15-PGDH overexpression induced an increase in caspase-3 
activity (Fig. 4F) and in the expression of the pro-apoptotic proteins Bax and Bid (Fig. 4G), 
whereas the expression of anti-apoptotic proteins Bcl-2 and Bcl-xL was decreased (Fig. 4H). 
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These results suggest that 15-PGDH may exert its anti-tumoral effects partially through 
induction of apoptosis. 
3.1.4. 15-PGDH decreases the growth of hepatoma cells in vivo.  
To further analyze the effect of 15-PGDH on hepatoma cell growth in vivo, HepG2 cells were 
targeted to modulate 15-PGDH levels and cells were subcutaneously injected into athymic 
nu/nu mice. The mice were followed by the observation of xenograft growth for 3 weeks. We 
found that 15-PGDH led to a significant reduction in the volume and weight of the tumor 
comparing with the mice injected with control vector. Transfection with siPGDH increased 
the volume and the weight of tumors vs. scRNA (Fig. 4I-J). These results agree with the in 
vitro data and suggest that 15-PGDH inhibits the proliferation of hepatoma cells by inducing 
apoptosis.  
3.1.5. 15-PGDH expression in murine models of HCC.  
To determine the role of 15-PGDH in HCC development, mice were injected with DEN (25 
mg/kg) at the 14th postnatal day and sacrificed 10 and 40 wk after treatment. Plasma levels 
of liver injury markers after DEN treatment were analyzed in supplementary Table I. There 
was an important increase of AST and ALT after DEN treatment compared with the 
untreated mice. In addition, morphometric analysis revealed important differences in the 
number and size of detectable tumors at 40 wk compared with 10 wk after DEN treatment 
(Fig. 5A). This would be coupled with the histopathological analysis of the liver biopsies 
indicating preneoplasic lesions (8%) in mice at 10 wk after DEN and HCC (100%) in mice at 
40 wk after DEN and lung metastases (25%) (Table I). Histological analysis confirmed that 
all tumors at 40 wk after DEN treatment corresponded to liver carcinomas (Fig. 5B). Tumors 
at 40 wk after DEN were positive for α-fetoprotein expression (not shown). Furthermore, 15-
PGDH decreased at 10 wk after DEN treatment and was negligible in the non-tumor and 
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tumor tissue at 40 wk after treatment compared with normal liver (Fig. 5C). We also 
analyzed the profile of 15-PGDH in the double transgenic mice c-myc/TGF-α, a genetic 
model of HCC. Plasma levels of liver injury markers and the incidence of pathological signs 
are given in supplementary Table II. The morphometric analysis revealed significant 
differences in the number and size of detectable tumors in c-myc/TGF-α mice at 9 months 
old compared with 5 months-old mice (Fig. 5D). Most of the c-myc/TGF-α double transgenic 
mice sacrificed at 5-months-old-age had preneoplasic foci (93.3%) (supplementary Table II). 
Furthermore, histological analysis of liver biopsies showed a tendency to develop adenomas 
(26.7%). After 9 months, >89% of Tg mice displayed HCC (supplementary Table II and Fig. 
5E). Interestingly, 15-PGDH protein levels were undetectable in the tumors generated by c-
myc/TGF-α stably expression (Fig. 5F) compared with normal liver. The double transgenic 
was verified by c-myc and TGF-α protein expression (Fig. 5F).  
3.1.6. Downregulation of 15-PGDH mRNA and protein expression in HCC human 
biopsies. 
To extend our studies and assess the biological relevance of these observations in cell lines 
and murine models, we examined the 15-PGDH expression in 11 clinical samples of HCC 
and normal liver in a tissue microarray for immunohistochemistry analysis. A high 15-PGDH 
expression in normal liver tissue was detected (Fig. 6Aa), whereas in HCC tissue biopsies 15-
PGDH was significantly lesser expressed (Fig. 6Ab, c and 6B). Immunoreactivity of 15-
PGDH protein ranged from 61% to 0.09% vs. normal liver (100%, Fig. 6B). The average of 
15-PGDH immunoreactivity measurements was statistically significant compared with normal 
liver (Fig. 6C). In agreement with those observations, mRNA 15-PGDH  expression in 18 
individual tumoral (T) and paired non-tumoral (NT) HCC human samples showed higher 
levels in NT tissue compared to T tissue (P=0.0322) (Fig. 6D). These data support the 
hypothesis that 15-PGDH expression is downregulated in HCC. 
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4. DISCUSSION 
In this study we have analyzed the regulation of the expression of 15-PGDH in hepatoma cell 
lines, murine models of HCC and human HCC specimens. Our results show that 15-PGDH is 
downregulated in human hepatoma cells with a high COX-2 and mPGES-1 expression, in 
chemical and genetic murine models of HCC and in human HCC biopsies. Moreover, 15-
PGDH expression is suppressed by EGF and HGF mainly involving PI3K, ERK and 
p38MAPK activation, which supports cell viability. Conversely, ectopic expression of 15-
PGDH induces apoptosis in hepatoma cells and decreases the growth of hepatoma cells in 
nude mice whereas the silencing of 15-PGDH increased the tumor formation by promote 
increased in cell viability. 
Several lines of evidence suggest that COX-2 signaling is implicated in hepatocarcinogenesis 
and that COX-2 inhibitors prevent HCC cell growth in vitro and in animal models (Kern et 
al. , 2004). Increased COX-2 expression has been found in human HCC; however, although 
COX-2 is elevated in the early stages of HCC, many questions remain unsolved regarding the 
sufficiency of COX-2 to induce/contribute to tumorigenesis (Cusimano, Fodera, 2009). Our 
previous work demonstrated that constitutive COX-2 expression in mice liver is not 
sufficient to enhance malignant transformation induced by DEN (Llorente Izquierdo, 
Mayoral, 2011). Regarding mPGES-1, it participates in various pathophysiological states in 
which COX-2 is involved. Consistent with the role of mPGES-1 for PGE2 synthesis, 
mPGES-1 knockdown has been shown to reduce PGE2 levels and reduce tumor proliferation 
and/or invasiveness in several tumor cell types through a EGR1/β-catenin signaling axis 
(Donnini, Finetti, 2011, Sasaki, Kamei, 2011). The third enzyme involved in PGE2 
homeostasis, 15-PGDH, also plays an important role in carcinogenesis. 15-PGDH is down-
regulated and is a tumor suppressor in gastrointestinal, breast and lung cancers (Ding, Tong, 
2005, Lou et al. , 2012, Wolf, O'Kelly, 2006, Yan, Rerko, 2004). 15-PGDH catalyzes the rate 
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limiting step of PG catabolism and thus represents a physiological antagonist of COX-2 
(Backlund et al. , 2005). Recent emerging evidence suggests that elevated PGE2 in cancers 
may be the result of enhanced COX-2 mediated PGE2 synthesis, but also to reduced 15-
PGDH-dependent degradation. Although COX-2 expression in HCC has been extensively 
studied there are few data concerning mPGES-1 and 15-PGDH involvement in HCC 
(Cusimano, Fodera, 2009, Kern, Schoneweiss, 2004, Koga et al. , 1999, Llorente Izquierdo, 
Mayoral, 2011). Lim et al. reported that omega-3 polyunsaturated fatty acids inhibited PGE2 
signaling through decreased of COX-2 and expression of 15-PGDH in HCC cell lines (Lim 
et al. , 2009). In hepatoma cell lines our data show different levels of COX-2, mPGES-1 and 
15-PGDH. Interestingly, there was a direct linear correlation between COX-2 and mPGES-1 
and an inverse correlation between COX-2 and 15-PGDH. PGE2 levels paralleled COX-2 and 
mPGES-1 expression.  
The EGF and HGF signaling pathways upregulate COX-2 expression in different cancer cell 
types and downregulate 15-PGDH expression in several carcinomas (Donnini, Finetti, 2011, 
Moore, Greenhough, 2009, Tai, Chi, 2011). Inhibition of Met expression increased 15-PGDH 
levels and both ERK and Akt signaling pathways were required for the COX-2 rise and 15-
PGDH decrease (Moore, Greenhough, 2009). Backlund et al. showed that a tyrosine kinase 
inhibitor, Erlotinib, increased the levels of 15-PGDH in colorectal cancer cell lines and this 
effect was mimicked by a MEK inhibitor (Backlund, Mann, 2005). PI3K/AKT and 
Ras/MAPK kinase signaling cascades which are downstream EGFR engagement, are 
implicated in the down-regulation of 15-PGDH induced by EGF. Suppression of ERK activity 
blocked the effect of EGF on 15-PGDH, whereas a MEK kinase inhibitor was capable of 
suppressing the expression of Slug and Zeb1 which repress the expression of 15-PGDH 
(Yang et al. , 2007). Moreover, Snail and Slug induced by EGF receptor signaling recruit 
histone deacetylases (HDACs) which bind to conserved E-box elements present in the 
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promoter of 15-PGDH and repress its transcription (Mann et al. , 2006). Our results agree 
with these data being 15-PGDH downregulated in HCC cells by EGF and HGF through PI3K, 
p38 MAPK, MEK/ERK MAPK and EGFR signaling dependent pathways. 
An important question in this area is to address whether 15-PGDH and COX-2 are 
reciprocally regulated in cancer cells. In human lung adenocarcinoma cells, A549, which 
exhibit the capacity of expressing both COX-2 and 15-PGDH, overexpression of COX-2 
resulted in downregulation of 15-PGDH and increased expression of 15-PGDH impedes the 
rise of COX-2 induced by IL-1β. The lower the endogenous level of 15-PGDH expression 
present in the cells is, the higher the levels of COX-2 are. Since a catalytically inactive 15-
PGDH mutant also impeded the expression of COX-2 induced by IL-1β it became clear that 
the inhibition of COX-2 expression was not dependent on the catalytic activity of 15-PGDH 
(Tai, 2011). Song et al. reported similar results in gastric cancer cells where 15-PGDH 
expression increased as COX-2 was repressed by COX-2-siRNA (Song et al. , 2011). In the 
case of liver, CHL cells were shown to have the capacity of expressing COX-2, mPGES-1 
and 15-PGDH. COX-2 was rarely observed under basal conditions, whereas 15-PGDH was 
usually present. Expression of COX-2 induced by EGF and HGF was in parallel with a drop 
of 15-PGDH in CHL cells; interestingly, this EFG-induced reduction of 15-PGDH was also 
observed in the presence of a potent and selective COX-2 inhibitor (DFU), reinforcing the 
view of a minimal contribution of PGs on this cross-regulation. Indeed, exogenous PGE2 also 
did not influence of 15-PGDH levels. Moreover, when HepG2 and CHL cells were 
transfected with a siRNA to downregulate 15-PGDH, COX-2 levels increased and the 
contrary was found with ectopic expression of 15-PGDH. Even more, downregulation of 
COX-2 in WRL68 cells increased 15-PGDH expression. These results suggest an activity-
independent interplay between COX-2 and 15-PGDH in hepatoma cells, perhaps in the same 
way as reported by Tong et al. that proposed a direct interaction of 15-PGDH with the COX-2 
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3’UTR through its AU-rich sequences that destabilize its mRNA blocking translation (Tong et 
al. , 2006).  
There are different reports concerning the role of 15-PGDH in in vivo models of colon cancer. 
In the APC 
Min
 mouse that spontaneously develop preinvasive adenomas that recapitulate 
many aspects of the human syndrome, familial adenomatous polyposis coli pathology, 15-
PGDH was observed in the well differentiated villi from wild type mice, whereas it was 
absent in adenomas  from APC 
Min/+
 mice (Backlund et al. , 2008, Mann, Backlund, 2006). 
Using a 15-PGDH knockout mouse model, Yan et al. showed a remarkable sensitization to 
colon tumor induction by azoxymethane and this deficiency in APC
Min
 resulted in an 
eightfold increase in colon tumor development vs. APC
Min
 mice expressing 15-PGDH 
(Myung et al. , 2006, Yan et al. , 2009). Our results in a chemical model of liver cancer 
induced with DEN and in the c-myc/TGF-α double transgenic mice show an important 15-
PGDH expression in the normal liver tissue but a decrease in the tumoral liver tissue 
(Llorente Izquierdo, Mayoral, 2011, Santoni-Rugiu, Jensen, 1998). In agreement with this 
data we observed a decreased viability in HepG2 cells expressing of 15-PGDH both in in 
vitro and in in vivo assays when explanted in nude mice, these effects being reverted after 
reduction of 15-PGDH levels.  
Moreover, 15-PGDH expression has been also analyzed in human colorectal cancer and in 
human lung cancer. The expression pattern of 15-PGDH was reduced in microdissected early 
hyperplasic lesions and in colorectal carcinomas suggesting that 15-PGDH plays a role in 
prevention of tumor progression (Ding, Tong, 2005, Lou, Jing, 2012, Mann, Backlund, 2006). 
Our data in human biopsies of HCC show a high 15-PGDH expression in normal liver tissue 
and a lesser content in ca. 90%, in tumor tissue biopsies from patients with HCC at the time 
that hepatoma cells overexpressing 15-PGDH show enhanced levels of pro-apoptotic proteins 
and to be more prone to activate caspase 3. 
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All this data suggest that 15-PGDH is a promising target for chemoprevention. Discovery and 
development of agents improving 15-PGDH expression and/or activity in HCC cells will 
provide additional approaches to cancer chemoprevention. Dexamethasone and other 
glucocorticoids were found to induce the expression of 15-PGDH in lung cancer cells (Tong 
and Tai, 2005). Non-steroidal anti-inflammatory drugs (NSAIDs) have been also evaluated 
exhibiting flurbiprofen the best capacity to induce 15-PGDH (Tai, Chi, 2011). Furthermore, 
peroxisome proliferator-activated receptor γ ligands such as thiazolidinediones inhibit lung 
cancer cell growth by decreasing PGE2 production through induction of 15-PGDH (Hazra et 
al. , 2007). Rosiglitazone specifically decreased expression of Snail which is involved in 15-
PGDH suppression (Choudhary et al. , 2010). In this sense and while we were preparing this 
manuscript, Lu et al. reported that 15-PGDH inhibits HCC growth through an alternative 
mechanism involving 15-keto-PGE2/PPARγ-mediated activation of p21
WAF1/Cip1
 signaling 
cascade (Lu et al. , 2013). Finally a promising target is the prostaglandin transporter (PTG) 
which may collaborate with 15-PGDH to inactivate PGE2 (Holla et al. , 2008).  
 In summary, we have found that the prostaglandin catabolic enzyme, 15-PGDH is 
downregulated in those human hepatoma cells with a high COX-2 and mPGES-1 expression, 
in chemical and genetic murine models of HCC and in human liver HCC biopsies and that 
over expression of 15-PGDH induces apoptosis in hepatoma cells. These results extend 
previous observations in other human cancers and suggest that 15-PGDH may function as a 
relevant tumor suppressor in HCC. 
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FIGURE LEGENDS 
Fig. 1. 15-PGDH and COX-2 correlate inversely in HCC cell lines. Cells were plated in 100-
mm dishes and grown to 60% confluence in culture medium supplemented with 10% FBS and 
subsequently placed in serum starved for 6 h. Total cellular extracts or RNA were obtained 
from hepatic cells lines. (A) COX-2 (72kDa), mPGES-1 (17 kDa) and 15-PGDH (25 kDa) 
protein expression were analyzed by Western blot of cell lysates (25 g/lane). The protein 
expression was normalized to that -actin. Densitometric analysis of COX-2, mPGES-1 and 
15-PGDH expression are referring to human hepatocytes (HH) as 1 and expressed as fold 
basal expression. A representative Western blot is shown. (B-C-D) COX-2, mPGES-1 and 
15-PGDH mRNA were analyzed by real-time PCR. The mRNA amounts were calculated as 
relative expression (RE) and normalized with 36b4 mRNA levels. Values represent relative 
fold change to HH. (E) Prostaglandin E2 concentration was determined by enzyme 
immunoassay using the cell supernatants. (F) The inverse correlation between COX-2/15-
PGDH protein expression ratio in hepatic cells lines is graphically depicted. The coefficient of 
determination (R
2
) was calculated. Data are means ± SD of at least three independent 
experiments. **P<0.01, *P<0.05 vs. HH. 
Fig. 2. EGF and HGF promote an increase of COX-2 and mPGES-1 and decrease 15-
PGDH protein levels in the CHL hepatocyte-like cell line. Cell cultures to 60% confluence 
were placed in serum starved for 6 h. Subsequently, the culture medium was replaced with 
fresh medium containing 1% FBS and then CHL cells were treated with different 
concentrations of EGF or HGF for 48 h or with 50 ng/ml of EGF at different time points and 
then obtained cells lysates or RNA. COX-2, mPGES-1 and 15-PGDH protein expression were 
determined as described in Fig. 1. (A) Analysis COX-2, mPGES-1 and 15-PGDH expression 
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by Western blot after treatment with different concentrations of EGF (B) Analysis COX-2, 
mPGES-1 and 15-PGDH expression by Western blot after 50 ng/ml of EGF at different time 
points (C) Analysis of COX-2 and mPGES-1 mRNA after 6 h of EGF treatment and 15-
PGDH mRNA at different time points by real-time PCR. The mRNA amounts were 
calculated as relative expression and normalized with 36b4 mRNA levels. Values represent 
relative fold change to unstimulated cells. (D) Analysis COX-2, mPGES-1 and 15-PGDH 
expression by Western blot after treatment with different concentrations of HGF. Data are 
means ± SD of at least three independent experiments. **P<0.01, *P<0.05 vs. unstimulated 
cells. 
Fig. 3. EGF downregulates 15-PGDH through EGFR, PI3K, MEK /ERK-MAPK and p38-
MAPK signaling pathways in CHL cells. CHL cells were treated or not with different 
pharmacological inhibitors during 1 h as described in methods and subsequently stimulated 
with 50 ng/ml of EGF for 48 h. COX-2 and 15-PGDH protein expression were analyzed as 
described in Fig. 1 and 2 (A) Analysis of COX-2 and 15-PGDH expression by Western blot 
(B) effect of 5µM DFU and 5 µM PGE2 on the 15-PGDH expression. Data are means ± SD of 
at least three independent experiments. **P<0.01, *P<0.05 vs. unstimulated cells. #P<0.05 vs. 
stimulated cells with EGF. 
Fig. 4. 15-PGDH expression decreases HCC cell viability and induces apoptosis. HepG2 
cells were seeded in a 6-well plate (3x10
5
cells/well) at 60% confluence and transfected with  
pcDNA3/15-PGDH (3 µg), pcDNA3 (3 µg), 30 nM siPGDH or 30 nM scRNA as described in 
Methods (A) Analysis of 15-PGDH expression by for Western blot. (B)  Cell viability (fold 
basal) was determined by the MTT assay. (C-D) Analysis of cell-cycle distribution by PI 
staining of HepG2 transfected cells. The analysis was performed using the percent of 
frequencies in each cycle phase (number of cells vs. relative intensity). (E) Apoptosis was 
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detected by flow cytometry using annexin V-FITC apoptosis detection kit.  (F) Caspase-3 
activity was determined by CaspGLOW fluorescein active caspase-3 staining kit. The 
protease activity is represented by fluorescence arbitrary units (a.u.)/g of total protein, 4.76 
a.u. corresponding to Lipofectamine is considered as 1.   (G-H) Analysis of pro-apoptotic and 
anti-apoptotic proteins expression by Western blot. Data are means ± SD of at least three 
independent experiments. **P<0.01, *P<0.05 vs. lipofectamine. HepG2 transfected cells with 
scRNA and siPGDH (I) or pcDNA3 and pcDNA3/15-PGDH (J) were subcutaneously 
injected into athymic nu/nu mice. The mice were followed by the observation of xenograft 
growth for 3 weeks. Tumor growth was measured every 2-3 days. Tumor volume (V) was 
monitored by measuring the length (L) and width (W) with calipers and calculated with the 
formula (L x W
2
) x 0.5. At 21 days after injection, mice were killed and tumors were weighed 
after necropsy. *P<0.05 vs. the scRNA or vs. the pcDNA3. Data are means ± SD of eight 
animals per condition.  
Fig. 5. 15-PGDH is decreased in murine models of HCC.  To induce HCC, DEN (25 mg/kg) 
was injected i.p. into 14 day-old mice. Mice were sacrificed at 10 or 40 weeks after DEN 
treatment and then the liver obtained for protein extracts. (A)  Morphometric analysis of 
tumor foci number and maximal size at 10 and 40 wk of DEN treatment. (B) H&E analysis of 
liver sections in mice at 10 and 40 wk of DEN treatment. Preneoplastic lesion (left panel) and 
HCC lesions (right panel) are indicated by arrows. Inset: Lung metastases (C) Western blot 
representative of 15-PGDH  expression in tumor (T) or non-tumor (NT) liver tissue after DEN 
treatment compared with normal liver and normalized with αp85. (D) Morphometric analysis 
of tumor foci number and maximal size at 5 and 9 months-old-age c-myc/TGF-α  mice. (E) 
H&E staining of liver sections showing HCC with trabecular pattern, cytological atypias and 
nuclear polymorphisms in c-myc/TGF-α mice at 9 months-old-age (right panel). A sharply 
demarcated hepatocellular adenoma with enlarged eosinophilic hepatocytes is shown at 5 
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months-old-age (left panel) (F) 15-PGDH protein expression in liver homogenates from c-
myc/TGF-α mice at 5 and 9 months-old-age detected by Western blot and normalized with 
αp85. The double transgenic was verified by c-myc and TGF-α protein expression. The 
photographs were taken with a Color View Camera in a Vanox Olympus microscope at 20X 
magnification. The bar corresponds to 100µm and lesions are indicated by arrows. Data are 
means ± SD of the number of animals indicated in supplementary Table I and II per condition.  
**P<0.01, *P<0.05 vs. the corresponding matched animals. 
Fig. 6. 15-PGDH mRNA and protein expression is down-regulated in HCC human 
biopsies. 15-PGDH expression was analyzed in 11 clinical samples of human hepatocellular 
carcinomas and normal liver in a tissue microarray for immunohistochemistry analysis. (A) 
Representative microphotographs of normal liver (a) and HCC samples (b-c). 
Microphotographs were taken with an EnVision FLEX system at 20X magnification. The bar 
corresponds to 100µm (B) The immunoreactivity of 15-PGDH expression was quantified as 
described in material and methods. The graphs represent the fold basal of immunostained of 
HCC samples (b-l) compared with normal liver (a). (C) The immunoreactivity measures were 
pooled and then compared with normal liver. The graphs represent the fold basal of 
immunostained of HCC samples compared with normal liver. Data are means ± SD of 11 
HCC samples. ** P<0.01 vs. normal liver tissue. (D) 15-PGDH mRNA expression was 
analyzed in 18 individual tumoral and paired non-tumoral HCC tumors using real-time PCR.  
*P<0.05 vs. NT samples. 
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